[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Wang X., Zhang Q., Bao R., Zhang N., Wang Y., Polo-Parada L., Tarim A., Alemifar A., Han X., Wilkins H.M., et al
The pattern suggests that each additional receptor target provides incremental but meaningful improvements
For young men with clinically diagnosed hypogonadism (testosterone consistently below 300 ng/dL with symptoms), addressing obesity through Retatrutide treatment may resolve the condition without requiring testosterone replacement therapy
Both compounds produce clinically significant weight loss
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis MARKET DYNAMICS Stringent cost and payer controls OPPORTUNITIES Impact Level Increasing studies on oral GLP-1 Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis Rapid expansion of manufacturing capacity is driving growth across the pharmaceutical market, especially for high-demand drugs like GLP-1 analogs
